Clik here to view.
Updates on tau topography and propagation
Gaël Chételat, PhD, HDR, Inserm, Université de Caen-Normandie, Caen, France, discusses her talk about tau topography and propagation. She explains that understanding the propagation of tau is crucial...
View ArticleClik here to view.
Markers of of tau pathology in Alzheimer’s disease
Marco Bucci, PhD, Karolinska Institutet, Stockholm, Sweden, explains that plasma p-tau markers appear to be more indicative of amyloid traces than tau pathology specifically, highlighting the need for...
View ArticleClik here to view.
Interactions between Aβ and tau proteins in Alzheimer’s disease
Gaël Chételat, PhD, HDR, Inserm, Université de Caen-Normandie, Caen, France, discusses the interaction of amyloid beta (Aβ) and tau proteins in Alzheimer’s disease. Aβ has not been shown to be...
View ArticleClik here to view.
Sex differences in Alzheimer’s disease plasma biomarkers
While sex differences in the risk and presentation of Alzheimer’s disease (AD) are well-studied, little is known about how these extend to plasma biomarkers. Marta Milà-Alomà, PhD, Northern California...
View ArticleClik here to view.
Tau-targeted therapy landscape in Alzheimer’s disease
Bengt Winblad, MD, PhD, Karolinska Institutet, Solna, Sweden, discusses his thoughts on the importance of combined therapies targeting amyloid- and tau-pathology in treating Alzheimer’s disease. He...
View ArticleClik here to view.
Polygenic risk scores for Alzheimer’s disease in relation to cognitive change
Jenna Najar, MD, PhD, Sahlgrenska University Hospital, Gothenburg, Sweden & Amsterdam University Medical Center, Amsterdam, Netherlands talks about her research on polygenic risk scores (PRS) in...
View ArticleClik here to view.
How society needs to be made ready to treat Alzheimer’s disease
Bengt Winblad, MD, PhD, Karolinska Institutet, Solna, Sweden, provides insights into how society needs to be made ready for Alzheimer’s disease modifying therapies. He highlights that improved early...
View ArticleClik here to view.
Inspiring advances in research through scientific meetings
As Executive Organizer of AD/PD, Manfred Windisch, PhD, NeuroScios GmbH, Graz, Austria, discusses the importance of the conference in inspiring advances for Alzheimer’s disease. He highlights the...
View ArticleThe potential of brain-derived tau as a neurodegeneration biomarker
Bjørn-Eivind Kirsebom, PhD, University Hospital of North Norway, Tromsø, Norway, discusses brain-derived (BD) tau as a biomarker in Alzheimer’s disease (AD). BD-tau has emerged recently as an...
View ArticleClik here to view.
Metabolome-wide association studies in Alzheimer’s disease
Genome-wide association studies (GWAS) in Alzheimer’s disease (AD) have identified many risk loci, however the mechanisms by which these confer susceptibility to AD are poorly understood. Rui Pinto,...
View Article